It was announced today that Belfast-based, Intelesens Ltd. has been acquired by UltraLinq Healthcare, the Connected Health Platform of Renew Health Limited.
The acquisition of Intelesens, which specialises in intelligent, wearable, non-invasive, wireless vital signs monitoring devices for both the hospital and home patient monitoring markets, will assist UltraLinq in progressing its strategy of providing a cost-effective digital health platform focused on the improvement of cardiovascular healthcare globally.
Intelesens currently sells its products – Zensor, which assists in streamlining the medical referral pathway resulting in clinical and economic benefits, and Aingeal, which facilitates the monitoring of respiration rate, ECG, heart rate, motion and skin temperature in hospital patients – to healthcare providers in the UK, EMEA, ASEAN and North America. In 2011, the company won the prestigious Silicon Valley ‘Most Promising Technology Award’ for its technology.
Intelesens currently employs a team of 39 who will remain at its Heron Road site where the company manufactures a range of electrodes and devices.
Speaking this week, CEO of New York-based UltraLinq Healthcare, Stephen Farber said, "Intelesens has pioneered the development of proprietary world class algorithms for the detection of a range of cardiac arrhythmias from wireless sensors on the body. This technology, coupled with the team’s incredible knowledge of the space, will allow us to make huge strides towards our end goal of providing cost-effective tools to improve the delivery of cardiovascular care globally."
CEO of Intelesens, Aidan Langan added, "The Board of Intelesens believes that the deal with Ultralinq represents a tremendous opportunity for the company and its future development, as well as for the MedTech sector in Northern Ireland more generally. The acquisition has presented a great outcome for our shareholders and our staff are very excited about the ambitious plans."